The Ultimate Biotech Stock to Buy With $500 Right Now
The Ultimate Biotech Stock to Buy With $500 Right Now
Adria Cimino, The Motley FoolTue, February 24, 2026 at 8:50 AM UTC
0
Key Points -
This company is the global leader in its specialty area and has successfully expanded into other areas, too.
This player aims to generate $13 billion in sales this year.
10 stocks we like better than Vertex Pharmaceuticals ›
Biotech companies are all about innovation. These players are developing and using cutting-edge technologies to address a variety of diseases, and in many cases, their efforts are leading to game-changing products for patients. You can invest in them during the earliest stages of their story, and if they're successful, score an enormous win over time.
That involves some risk, though, as candidates may not always be successful -- and setbacks could weigh heavily on stock performance. So how can you benefit from the innovation of biotech, but at a lower risk level? By choosing a company that's further along in its growth story and has brought products to market, and at the same time continues to innovate.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Let's check out one that fits the bill. In fact, it's the ultimate biotech stock to buy with $500 right now.
A smiling investor holds a handful of bills at home.
Image source: Getty Images.
A market leader
This biotech company is Vertex Pharmaceuticals (NASDAQ: VRTX), the world's leading player in the cystic fibrosis (CF) treatment market. Vertex has changed the lives of CF patients and their families over the past several years. The company won approval for its first CF drug in 2012 and, since then, has continued to add to the portfolio, with the ability to now treat about 90% of the CF patient population.
Vertex's CF drugs are designed to fix a faulty protein made by the CFTR gene -- since genetic mutations are involved in this disease, it's challenging to develop one drug to handle every case. Now, Vertex's treatments can address most, but the company hasn't stopped there. It's working on a candidate to treat the cases that can't be helped by its current drugs. This ongoing innovation, as well as strong intellectual property, should fuel Vertex's leadership and growth in the years to come.
New growth drivers
On top of this, Vertex has two new growth drivers. The company won approval for Casgevy for blood disorders and Journavx for pain management in 2023 and 2025, respectively. These launches are ongoing, and trends are very positive. Casgevy is a gene editing treatment requiring a months-long process, so it's normal that this product takes a while to start delivering growth -- but now may be the moment shareholders were waiting for. Vertex expects non-CF products to bring in at least $500 million in revenue this year.
Advertisement
The company has called both products blockbuster opportunities, so we could be in the very early stages of this growth story right now. And Vertex forecasts as much as $13.1 billion in total revenue this year as the CF portfolio continues to deliver gains.
This leadership and ongoing innovation in CF, as well as new products, position Vertex for many years of strength -- and that's why it's the ultimate biotech to buy with $500 right now.
Should you buy stock in Vertex Pharmaceuticals right now?
Before you buy stock in Vertex Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 24, 2026.
Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Source: “AOL Money”
